[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neurodegeneration\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neurodegeneration":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,46,60,92,129,167,194,211,238],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100053348","phase-1-kisspeptin-to-quantify-gnrh-neuronal-function-in-health-and-disease-100053348",false,"NCT07224490","Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease","Inclusion Criteria\n\n* Female (ages 18-45 years) or Male (ages 18-60 years)\n* No current or recent use of a medication (including hormonal replacement) that, in the opinion of a study investigator, can modulate the reproductive axis or willing to complete an appropriate washout for that particular medication and its method of administration\n* For women, negative serum hCG pregnancy test\n* For cases, diagnosis of post-covid-19 syndrome\n* For controls, history of prior covid infection but no diagnosis of post-covid-19 syndrome\n\nExclusion Criteria\n\n* Any condition (medical, mental, or behavioral) that, in the opinion of a study investigator, would likely interfere with participation in\u002Fcompletion of the protocol or the interpretation of results\n* Active use of illicit drugs (not including marijuana)\n* For women,\n* Pregnant\n* Trying to become pregnant during protocol participation\n* Breast feeding\n* Surgical or natural menopause","ALL","18 Years","60 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The objective of this protocol is to use a case-control paradigm to compare the response to an intravenous administration of kisspeptin in individuals with and without post-covid-19 syndrome. The study subjects will receive a single bolus of kisspeptin.",[26,27,28,29],"Reproductive Disorder","Neurodegeneration","SARS-CoV 2","Long COVID",[31,27,28,32,29],"Reproductive disorder","Kisspeptin","RECRUITING","2026-07-09",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":37},"2026-03-10",{"date":41,"type":20},"2030-05",{"name":43,"class":44},"Stephanie B. Seminara, MD","OTHER",1,{"id":47,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":51,"conditions":52,"keywords":53,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":58,"leadSponsor":59,"locationsCount":45},"100610200","Inclusion Criteria\n\n* Female (ages 18-45 years) or Male (ages 18-60 years)\n* Normal blood pressure (systolic BP \\\u003C 140 mm Hg, diastolic \\\u003C 90 mm Hg)\n* Hemoglobin no less than 0.5 g\u002FdL below the lower limit of the sex specific reference range\n* No current or recent use of a medication (including hormonal replacement) that, in the opinion of a study investigator, can modulate the reproductive axis or willing to complete an appropriate washout for that particular medication and its method of administration\n* For women, negative serum hCG pregnancy test\n* For cases, diagnosis of post-covid-19 syndrome\n* For controls, history of prior covid infection but no diagnosis of post-covid-19 syndrome\n\nExclusion Criteria\n\n* Any condition (medical, mental, or behavioral) that, in the opinion of a study investigator, would likely interfere with participation in\u002Fcompletion of the protocol\n* Excessive alcohol consumption (\\>10 drinks\u002Fweek)\n* Active use of illicit drugs\n* For women,\n* Pregnant\n* Trying to become pregnant during protocol participation\n* Breast feeding\n* History of any of the following: bilateral oophorectomy (ovaries were removed), breast cancer, thromboembolic disease, coronary artery disease, stroke, thrombophilic disorders, or undiagnosed abnormal genital bleeding",{"count":19,"type":20},[23],"The objective of this protocol is to use a case-control paradigm to compare the response to an intravenous administration of kisspeptin in individuals with and without post-covid-19 syndrome. The study subjects will receive a single bolus of kisspeptin.\n\nThis study will utilize the technique of frequent blood sampling (q10 minutes) to provide detailed neuroendocrine characterization of endogenous LH secretion before and after kisspeptin administration. This frequency of blood sampling is required to define the features of LH pulses.",[26,27,28,29],[31,27,28,32,29],"2026-05-16",{"date":56,"type":37},"2026-05-19",{"date":39,"type":37},{"date":41,"type":20},{"name":43,"class":44},{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":67,"sex":15,"minAge":68,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":21,"phases":71,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":4},"100583240","neuromodulation-and-fmri-in-neurodegenerative-diseases-study-100583240","NCT06873750","Neuromodulation and fMRI in Neurodegenerative Diseases Study","A Pilot Study in Defining the Potential of Transcranial Alternating Current Neuromodulation for Stabilizing Memory and Improving Functional Connectivity in Neurodegeneration","Inclusion Criteria:\n\n1. Be at least 25 years of age;\n2. Have no contraindications to MRI\n3. Have received 8 or more years of formal education\n4. Be fluent in English\n5. Cohort a. must be followed at Sunnybrook Health Sciences Center\n\nCohort a:\n\n* Have been diagnosed with a suspected neurodegenerative disorder or traumatic brain injury (TBI) with memory deficits impacting functional status\n* In case of TBI, cognitive impairment has persisted at least three months post-injury\n* Received score of 16 or lower on the Mini Mental State Examination (MMSE)\n\nCohort b:\n\n* Have no prior diagnosis of a neurodegenerative disorder or post-traumatic brain injury cognitive deficits\n* Be experiencing healthy aging and be age and sex matched to Cohort a.\n\nExclusion Criteria:\n\n1. Have any contraindications to MRI\n2. Be pregnancy\n3. Have any major comorbid medical conditions (as determined by investigators - e.g., comorbid neurological diseases, uncontrolled hypertension or diabetes, malignancy) or major comorbid psychiatric conditions (as determined by investigators - e.g., schizophrenia or bipolar disorder)",true,"25 Years",{"count":70,"type":20},30,[72],"NA","In addition to neuronal loss, dysfunction in brain network connectivity has been identified as a correlate of cognitive deficits in neurodegenerative and post-traumatic brain injury states. Transcranial alternating current stimulation (tACS) has been suggested as a promising, non-invasive, method of normalizing network connectivity and hence improving cognition, notably memory. This study will examine the efficacy of tACS at improving working memory performance in patients with neurodegeneration and its correlation to changes in network connectivity, based on functional magnetic resonance imaging (fMRI) and electroencephalography (EEG) imaging data.",[75,76,27],"Mild Cognitive Impairment","Traumatic Brain Injury",[78,79,80,81],"Transcranial Alternating Current Stimulation","Neuromodulation","Functional Magnetic Resonance Imaging","Cognitive Assessment","NOT_YET_RECRUITING","2026-04-27",{"date":85,"type":37},"2026-05-01",{"date":87,"type":20},"2026-06-01",{"date":89,"type":20},"2028-12-01",{"name":91,"class":44},"Sunnybrook Health Sciences Centre",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":15,"minAge":99,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":21,"phases":102,"briefSummary":103,"conditions":104,"keywords":107,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":45},"100522879","moderate-versus-high-volume-light-moderate-intensity-exercise-for-people-with-moderate-parkinsons-disease-100522879","NCT06088355","Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease","HI-LITE","Inclusion Criteria:\n\nParticipants recruited for this study will be age 40 and older with diagnosis of \"definite\" PD based upon established criteria (Hughes, Daniel et al. 1992) and determined by a board-certified neurologist with specialty training in movement disorders. Individuals must have presented with asymmetric symptoms that included at least 3 of the cardinal signs of PD (rigidity, bradykinesia, tremor, postural instability), and must show clear symptomatic benefit (e.g., alleviated rigidity, bradykinesia, and tremor) from antiparkinsonian medications, e.g., levodopa (Kempster, Williams et al. 2007). They should be in H\\&Y stages 2, 2.5 and 3, and receive a Montreal Cognitive Assessment (MoCA) score \\>17 (Litvan, Goldman et al. 2012). Age 40 is the upper limit for young onset PD. We will not recruit individuals with a history of significant alcohol or drug use, nor habitual users of antipsychotics. We will observe patients while OFF their antiparkinsonian medications to avoid dyskinesia, and medication fluctuations that may impact neurophysiology and motor examination. We have successfully observed patients while OFF in several previous trials. The following inclusion criteria apply:\n\n* MoCA score \\>17\n* Able to walk with or without an assistive device at least 10 feet\n* Best corrected\u002Faided acuity better than 20\u002F70 in the better eye\n* Willingness to be randomized to a treatment group\n* H\\&Y stages 2, 2.5 and 3\n* Show clear symptomatic benefit (e.g., alleviated rigidity, bradykinesia, and tremor) from antiparkinsonian medications\n* Fluent in English to be able to comprehend and participate; older than 40 years; Diagnosis of definite Parkinson's disease by board certified Movement Disorders Neurologist, using standardized UK Brain Bank criteria\n\nExclusion Criteria:\n\nParticipants recruited for this study will be age 40 and older with diagnosis of \"definite\" PD based upon established criteria (Hughes, Daniel et al. 1992) and determined by a board-certified neurologist with specialty training in movement disorders. Individuals must have presented with asymmetric symptoms that included at least 3 of the cardinal signs of PD (rigidity, bradykinesia, tremor, postural instability), and must show clear symptomatic benefit (e.g., alleviated rigidity, bradykinesia, and tremor) from antiparkinsonian medications, e.g., levodopa (Kempster, Williams et al. 2007). They should be in H\\&Y stages 2, 2.5 and 3, and receive a Montreal Cognitive Assessment (MoCA) score \\>17 (Litvan, Goldman et al. 2012). Age 40 is the upper limit for young onset PD. We will not recruit individuals with a history of significant alcohol or drug use, nor habitual users of antipsychotics. The following exclusion criteria apply:\n\n* Untreated Major Depression and major psychiatric illness\n* History of stroke, or traumatic brain injury\n* Pure-tone threshold average sensitivity at 0.5, 1.0,and 2.0 kHz exceeds 40 dB\n* Alcohol abuse and\u002For use of antipsychotics\n* Planning to leave the area for \\>1 month during the study time period.\n* Taking moderate to high doses of beta-blockers with a resting heart rate below 60 beats\u002Fmin given that exercise intensity is measured through target heart rate.\n* Severe cardiac disease, including NYHA Class III or IV congestive heart failure, clinically significant aortic stenosis, history of cardiac arrest, use of a cardiac defibrillator, or uncontrolled angina\n* Other significant co-morbid disease that would impair ability to participate in the exercise-based intervention, e.g. renal failure on hemodialysis, excessive alcohol use (\\>14 drinks per wk)","40 Years",{"count":101,"type":20},123,[72],"Veterans with mid to later stage Parkinson's disease (PD) may not be able to work out as hard as they need to, to prevent brain cell loss. Maybe they could work out longer and more frequently to make up for this during their good times and good weeks and then rest during the bad weeks. The investigators will compare how effective working out a lot one week per month with a break of three weeks is to continuously exercising weekly with no breaks in people with mid stage PD. The investigators will look at how fast participants walk per minute, whether they become more physically active, the biochemicals in their blood, and at how stiff their blood vessels are before and after the exercise.",[105,106,27],"Parkinson Disease","Movement Disorders",[108,109,110,111,112,113,114,115,116,117,118],"dance","walk","Neurodegenerative","aging","exercise","high volume","frequency","intensity","duration","biomarkers","Parkinson's disease","2026-02-02",{"date":121,"type":37},"2026-02-05",{"date":123,"type":37},"2025-01-25",{"date":125,"type":20},"2029-06-02",{"name":127,"class":128},"VA Office of Research and Development","FED",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":67,"sex":15,"minAge":137,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":21,"phases":141,"briefSummary":142,"conditions":143,"keywords":151,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":45},"100620766","deciphering-the-effect-of-moderate-wine-consumption-on-healthy-aging-through-postprandial-extracellular-vesicles-100620766","NCT07361887","Deciphering the Effect of Moderate Wine Consumption on Healthy Aging Through Postprandial Extracellular Vesicles.","Deciphering the Effect of Moderate Wine Consumption on Healthy Aging Through Postprandial Extracellular Vesicles","(WINEVOME)","Inclusion Criteria\n\n* Healthy adult men and women aged 35 to 65 years.\n* Body Mass Index (BMI) between 18.5 and 29.9 kg\u002Fm².\n* Non-smokers or ex-smokers for at least 12 months.\n* Moderate alcohol consumers, defined as ≤2 units\u002Fday for men and ≤1 unit\u002Fday for women.\n* Normal fasting glucose and lipid profile at screening.\n* Willing and able to refrain from alcohol, polyphenol-rich foods, and intense exercise for 48 hours before each study visit.\n* Able to understand the study procedures and provide written informed consent.\n\nExclusion Criteria\n\n* History or clinical evidence of cardiovascular, hepatic, renal, thyroid, gastrointestinal, or metabolic diseases (including diabetes, dyslipidemia, or hypertension).\n* Use of medications or supplements known to affect glucose, lipid, or inflammatory metabolism (e.g., statins, corticosteroids, anti-inflammatory drugs).\n* Pregnancy or breastfeeding.\n* Recent blood donation (within the last 3 months) or planned blood donation during the study period.\n* Major weight change (\\>5% of body weight) within the last 3 months.\n* Participation in another clinical or biomedical study within the previous 3 months.\n* Known allergy or intolerance to wine, alcohol, or its components (e.g., sulfites).\n* History of alcohol abuse or inability to abstain from alcohol outside the study context.\n* Reluctance to receive information about incidental health findings arising from the study.\n* Any condition judged by the investigators to limit compliance or increase study risk (e.g., psychiatric disorders, inability to adhere to fasting requirements).","35 Years","36 Years",{"count":140,"type":20},8,[72],"This study aims to investigate how moderate wine consumption influences circulating extracellular vesicles (EVs) in healthy adults. EVs are small particles released by cells that carry proteins, lipids, and genetic material, and play important roles in communication between cells. Participants will consume a single serving of red or white wine, and blood samples will be collected before and after consumption to study changes in the composition and function of EVs. The study will also assess how these EVs affect vascular, immune, and brain-related cells. The results are expected to improve our understanding of how moderate wine intake contributes to cardiovascular and brain health.",[144,145,146,147,148,27,149,150],"Atherosclerosis Cardiovascular Disease","Obesity","Metabolic Syndrome","Metabolic Disorders","Inflammation","Neurodegenerative Disease","Alzheimer s Disease",[152,153,154,155,156,157],"blood-brain barrier","microglia","extracellular vesicles","lipidome","proteome","vascular disease","2026-01-14",{"date":160,"type":37},"2026-01-23",{"date":162,"type":37},"2025-11-01",{"date":164,"type":20},"2027-03-31",{"name":166,"class":44},"University of Seville",{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":15,"minAge":68,"maxAge":175,"enrollmentInfo":176,"targetDuration":4,"studyType":178,"phases":4,"briefSummary":179,"conditions":180,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":45},"100478957","serotonin-release-in-premotor-and-motor-pd-100478957","NCT05516732","Serotonin Release in Premotor and Motor PD","Evaluation of Serotonergic Neurotransmission in Premotor and Motor Parkinson's Disease.","FOX3","Inclusion criteria-\n\n* Subjects must understand the nature of the study and must provide signed and dated written HRA-approved informed consent in accordance with local regulations before any protocol-specific screening procedures are performed;\n* Males and females, age 25-85 years, inclusive;\n* Women of child-bearing potential must use protocol-defined contraceptive measures and must have a negative β-hCG test at screening. For sexually active subjects (except females of non-childbearing potential-e.g., at least 2 years postmenopausal or surgically sterile), condoms should be used in addition to other birth control methods for the duration of the study and for 3 months after the last administration of PET or SPECT ligands. These patients must be willing to remain on their current form of contraception for the duration of the study. All male subjects must agree to refrain from donating sperm for the duration of the study and for 3 months after the last administration of PET or SPECT ligands. Sexually active male subjects must agree to use condoms to protect their partners from becoming pregnant for the duration of the study and for 3 months after the last administration of PET or SPECT ligands (i.e. for 15 consecutive months following baseline PET and SPECT scans); agree to ensure that they and their partners are routinely using a medically approved contraceptive method. It is important that male subjects not impregnate others for the duration of the study and for 3 months after the last administration of PET or SPECT ligands;\n* Able and willing to participate in all scheduled evaluations, abide by all study restrictions, and complete all required tests and procedures;\n* Adequate visual and auditory acuity to complete the psychological testing;\n* In the opinion of the investigator, the subject must be considered likely to comply with the study protocol and to have a high probability of completing the study.\n\nExclusion criteria -\n\n* Subjects lacking capacity according to investigator judgement;\n* Subjects taking serotonin acting drugs such as antidepressants (i.e. tricyclic or selective serotonin reuptake inhibitors etc.);\n* Pregnancy or breastfeeding or intent to become pregnant in the next 18 months;\n* Subjects with current or a recent history of drug or alcohol abuse\u002Fdependence;\n* Subjects who have other neurological disorders and known intracranial co-morbidities such as stroke, hemorrhage, space-occupying lesions;\n* Presence of any clinically significant medical condition (including cardiovascular, respiratory, cerebrovascular, hematological, hepatic, renal, gastrointestinal, or other disease) that, based on the judgment of the investigator, is clinically unstable, is likely to deteriorate during the course of the study, could put the patient at risk because of participation in the study, could affect the subject's ability to complete the study, or could influence the study results;\n* History of suicidal behaviour or active suicidal ideation;\n* Within 1 year prior to screen or between screen and baseline (Day -1), any of the following: myocardial infarction; hospitalization for congestive heart failure; hospitalization for, or symptoms of, unstable angina; or syncope not related to PD;\n* History or presence of renal disease or impaired renal function;\n* Clinically important infection (e.g., chronic, persistent, or acute infection) within 30 days prior to screen or between screen and baseline (Day -1);\n* History of cancer within the last 5 years, with the exception of nonmetastatic basal cell carcinoma of the skin;\n* Clinically significant blood clotting or bleeding disorder, including clinically significant abnormal findings in laboratory assessments of coagulation or hematology;\n* Use of antipsychotic medication within 3 months prior to screen or between screen and baseline (Day -1);\n* Use of any anticoagulant within 30 days prior to baseline and follow-up PET scans;\n* Use of any oral corticosteroid within 30 days prior to baseline and follow-up PET scans;\n* Use of metoclopramide within 30 days prior to baseline and follow-up (Day -1);\n* Use of any thyroid medication within 30 days prior to baseline and follow-up (Day -1);\n* Regular use (e.g., taken \\> 3 days\u002Fweek) of narcotic pain medications within 30 days prior to baseline and follow-up (Day -1);\n* Presence of any of the following MRI contraindications: pacemaker; cardiac defibrillator; spinal cord or vagus nerve stimulator; aneurysm clip; artificial heart valve; recent coronary or carotid stent; ear implant; CSF shunt; other implanted medical device (e.g., Swan-Ganz catheter, insulin pump); or metal fragments or foreign objects in the eyes, skin, or body;\n* Negative modified Allen test in both hands, unless the brachial artery is used for arterial cannulation;\n* Claustrophobia or history of back pain that makes prolonged laying on the PET or MRI scanner intolerable;\n* History of severe skin allergy;\n* Patients who had previous surgery for PD (including but not limited to deep brain stimulation \\[DBS\\] or cell transplantation);\n* Patients who are treated with duodopa or apomorphine;\n* Initiation or change in pharmacologic therapy for symptoms of PD within 30 days prior to screen or between screen and baseline and follow-up (Day -1).\n* GDS score greater than or equal to 10 (GDS score of 5 - 9 requires Investigator discretion to enter study).\n* STAI Form Y-1 greater than or equal to 54 requires Investigator discretion to enter study.","85 Years",{"count":177,"type":20},42,"OBSERVATIONAL","In this study, the investigators aim to provide a deeper understanding of Parkinson's disease and find a biomarker of Parkinson's disease. This is done using imaging scans called Positron Emission tomography (PET), Single Photon Emission Computed Tomography (SPECT), and Magnetic Resonance Imaging (MRI). The findings will provide a deeper understanding of the brain changes in Parkinson's disease. More importantly, this study will help with the discovery and development of new medications aiming to delay progression of Parkinson's disease symptoms",[105,181,182,183,27,184],"Parkinson's","Parkinson's Disease","Neurodegenerative Diseases","Positron Emission Tomography","2025-10-01",{"date":187,"type":37},"2025-10-07",{"date":189,"type":37},"2022-07-01",{"date":191,"type":20},"2026-06-30",{"name":193,"class":44},"University of Exeter",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":67,"sex":15,"minAge":68,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":178,"phases":4,"briefSummary":204,"conditions":205,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":206,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":210,"locationsCount":45},"100478956","longitudinal-investigation-of-i2bs-in-pd-100478956","NCT05516719","Longitudinal Investigation of I2BS in PD","Longitudinal Investigation of Imidazoline-2 Binding Site as a Novel Marker of Disease Progression in Parkinson's Disease: An [11C]BU99008 PET Study","FOX_2","Inclusion criteria\n\n* All subjects must be judged by the investigator able to understand the nature, design, and procedures of the study and must be able to provide a signed and dated informed consent in accordance with Good Clinical Practice (GCP), International Conference on Harmonization (ICH), and local regulations.\n* All subjects must be willing and able to comply with scheduled visits, required study procedures and laboratory tests.\n* All subjects must be able to travel to the research sites for the study procedures.\n* Age 25 years or older.\n* For female subjects: They must be either of non-childbearing potential (either surgically sterile or post- menopausal - defined as 12 months of spontaneous amenorrhea), or, if of childbearing potential, subjects must demonstrate to be non-pregnant (as demonstrated by negative urine β-HCG test at screening), non-breastfeeding.\n* All subjects must comply with highly effective contraceptive measures. A highly effective contraceptive measure is defined as a measure that can achieve a failure rate of less than 1% per year when used consistently and correctly. These methods are listed in more detail below:\n\nOral, intravaginal, or transdermal combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation;\n\nOral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation:\n\nIntrauterine device (IUD)\n\nIntrauterine hormone-releasing system (IUS)\n\nBilateral tubal occlusion\n\nVasectomised partner\n\nSexual abstinence\n\n* For sexually active male subjects, they must agree to use condoms to protect their partners from becoming pregnant for the duration of the study and for 3 months after the last administration of PET or SPECT ligands. They must also agree to ensure that they and their partners are routinely using a medically approved contraceptive method. It is important that male subjects not impregnate others for the duration of the study and for 3 months after the last administration of PET or SPECT ligands.\n* All subjects must have adequate visual and auditory acuity according to investigator's judgement to complete the psychological testing.\n* All subjects must have no use of medications with known interaction with I2BS (e.g. idaxozan, efaroxan, yohimbine, atomoxetine, atipamezole, mianserin, mirtazapine, clonidine, guanfacine, guanabenz, guanethidine, xylazine, tizanidine, tedetomidine, methyldopa, fadolmidine, dexmedetomidine)\n* For subjects taking any drugs that might interfere with dopamine transporter SPECT imaging (neuroleptics, metoclopramide, alpha methyldopa, methylphenidate, reserpine, or amphetamine derivative) must be willing and able from a medical standpoint to hold the medication for at least 5 half-lives prior to screening DaTSCANä imaging.\n\nExclusion criteria\n\n* Subjects lacking capacity according to investigator's judgment;\n* Subjects with a clinical diagnosis of dementia as determined by the investigator;\n* Subjects with current or a recent history of drug or alcohol abuse\u002Fdependence;\n* Current treatment with anticoagulants (e.g. warfarin, heparin) that might preclude the arterial cannulation and the safe completion of the lumbar puncture.\n* Condition that precludes the safe performance of routine lumbar puncture, such as prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant coagulopathy or thrombocytopenia.\n* Negative Allen test in both hands,\n* Use of any of the following drugs that might interfere with dopamine transporter SPECT imaging: neuroleptics, metoclopramide, alpha methyldopa, methylphenidate, reserpine, or amphetamine derivative, within 5 months of Screening.\n* Use of any medications with known actions on I2BS (e.g. idaxozan, efaroxan, yohimbine, atomoxetine, atipamezole, mianserin, mirtazapine, clonidine, guanfacine, guanabenz, guanethidine, xylazine, tizanidine, tedetomidine, methyldopa, fadolmidine, dexmedetomidine);\n* Use of investigational drugs or devices within 60 days prior to Baseline (dietary supplements taken outside of a clinical trial are not exclusionary, e.g., coenzyme Q10).\n* History of cancer within the last 5 years, with the exception of non-metastatic basal cell carcinoma of the skin.\n* Subjects with current or recent history of drug or alcohol abuse\u002Fdependence.\n* Contraindication to MRI, such as presence of metal devises or implants (e.g. pacemaker, vascular- or heart- valves, stents, clips), metal deposited in the body (e.g. bullets or shells), or metal grains in the eyes;\n* Claustrophobia or history of back pain that makes prolonged laying on the PET, SPECT, or MRI scanner intolerable.\n* Previously obtained MRI scan with evidence of clinically significant neurological disorder (in the opinion of the Investigator).\n* Presence of any clinically significant medical condition (including cardiovascular, respiratory, cerebrovascular, hematological, hepatic, renal, gastrointestinal, or other disease) that, based on the judgment of the investigator, is clinically unstable, is likely to deteriorate during the course of the study, could put the patient at risk because of participation in the study, could affect the subject's ability to complete the study, or could influence the study results;\n* History of suicidal behavior or active suicidal ideation;\n* Pregnancy or breastfeeding or intent to become pregnant in the next 18 months;",{"count":203,"type":20},44,"In this study, the researchers aim to find a biomarker of PD. Using imaging scans called Positron Emission tomography (PET), Single Photon Emission Computed Tomography (SPECT), and Magnetic Resonance Imaging (MRI). The PET and SPECT scans use small amounts of radiation and specific compounds called tracers, to study chemical changes in the brain in a way not possible with any other procedure. The MRI uses magnetic fields to generate images of brain structure and function",[181,105,182,183,27,184],{"date":187,"type":37},{"date":208,"type":37},"2021-11-01",{"date":191,"type":20},{"name":193,"class":44},{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":67,"sex":15,"minAge":16,"maxAge":217,"enrollmentInfo":218,"targetDuration":220,"studyType":178,"phases":4,"briefSummary":221,"conditions":222,"keywords":224,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":237},"100569187","tau-petct-in-various-tau-related-disease-patients-100569187","NCT06690983","Tau PET\u002FCT in Various Tau-Related Disease Patients","Inclusion Criteria:\n\n\\- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled Tau PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n\\- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.","80 Years",{"count":219,"type":20},500,"7 Days","To evaluate the potential usefulness of 18F-S16\u002FT807 positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various Tau-related disease patients.",[223,183,27],"Tauopathies",[225,226,227],"PET\u002FCT","MRI","Tau","2025-02-07",{"date":230,"type":37},"2025-02-11",{"date":232,"type":37},"2018-08-01",{"date":234,"type":20},"2027-12-01",{"name":236,"class":44},"Tianjin Medical University",2,{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":67,"sex":15,"minAge":99,"maxAge":245,"enrollmentInfo":246,"targetDuration":4,"studyType":178,"phases":4,"briefSummary":248,"conditions":249,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":237},"100475283","china-longitudinal-aging-and-cognitive-impairment-study-100475283","NCT05468905","China Longitudinal Aging and Cognitive Impairment Study","CLACIS","Inclusion Criteria:\n\nInclusion Criteria:\n\n1. Cognitive normal aging (CN) 1. 40 years and older , without cognitive impairment, MMSE≥22 2. Informed consent is signed by the participant\n2. Subjective cognitive impairment (SCI) Participants aged 40 and older, with absence of dementia (by DSM IV and DSM V) criteria. Normal age-, sex-, and education-adjusted performance on standardized cognitive tests, which are used to classify mild cognitive impairment (MCI) or prodromal AD. Self-experienced persistent decline in cognitive capacity in comparison with a previously normal status and unrelated to an acute event. Answering \"yes\" to both of the following questions: \"Do you feel like your memory or thinking is becoming worse?\" and \"Does this concern you?\"\n3. Mild cognitive impairment (MCI) 1. 40 years and older 2. Diagnosis according to 2004 Peterson's MCI criteria. 3. Clinical Dementia Rating (CDR) = 0.5. 4. Memory loss is prominent, and may also be with other cognitive domain impairment.\n\n   5\\. Insidious onset, slow progress.\n4. Alzheimer's disease (AD)\n\n   1. 50 years and older\n   2. Dementia is diagnosed according to the criteria described by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-R). The diagnosis of AD according to the National Institute of Neurologic and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS- ADRDA) or National Institute on Aging and the Alzheimer's Assocation (NIA-AA) criteria.\n   3. Subjects and their informed persons can complete relevant and follow-up examinations.\n   4. Subjects or their authorized legal guardians sign the informed consent. Vascular cognitive impairment (VCI)\n\n   1\\. 40 years and older 2. Diagnosis according to the criteria for small vessel VCI, with the following three core elements:\n\n   1\\) Cognitive impairment: memory decline can be highlighted 2) Vascular factors 3) Causal relationship between cognitive impairment and vascular factors 3.Cognitive impairment lasts for 3 months or more, and the CDR global score ≥0.5 point.\n\n   4\\. All patients need to meet the following MRI criteria:\n   1. Multiple (≥3) small infarcts (3-20 mm in diameter) with or without any degree of white matter lesions (WML); or moderate to severe WML (Fazekas score ≥ 2) , with or without small infarction; or ≥ 1 small infarct in key parts of the cortex, such as: caudate nucleus, globus pallidus, thalamus et al.\n   2. No WML caused by cortical infarction, watershed infarction, hemorrhage, hydrocephalus, or other causes (such as multiple sclerosis).\n   3. No hippocampus or entorhinal cortex atrophy, Medial Temporal Lobe Atrophy (MTA)≤ 1 point.\n\n   5\\. Subjects and their informed persons can complete relevant and follow-up examinations.\n\n   6\\. Subjects or their authorized legal guardians sign the informed consent.\n\n   Exclusion Criteria:\n\n   Cognitive normal aging (CN)\n   1. any disease that can cause cognitive impairment (such as Alzheimer's disease, dementia with Lewy bodies (DLB), frontotemporal dementia (FTLD), Parkinson's disease dementia (PDD), intracranial masses that impair cognition, history of severe brain trauma, normal pressure hydrocephalus, cerebrovascular disease with obvious clinical symptoms, etc.\n   2. sequelae after previous history of severe central nervous system infection, multiple sclerosis, autoimmune encephalitis, Hashimoto's encephalopathy, etc.\n   3. previous history of instable epilepsy\n   4. systemic diseases affect the central nervous system, for abnormal liver and kidney functions (abdominal dialysis, hemodialysis, AST≥3× upper limit of normal value (ULN), ALT≥3× upper limit of normal value (ULN) or total bilirubin ≥2×ULN\n   5. history of hereditary diseases that affect cognitive function (such as Huntington's disease, down syndrome, CADASIL, adrenal leukodystrophy, mitochondrial encephalopathy, etc.)\n   6. long-term heavy drinking history (alcohol content more than 42 degree liquor, more than 150g\u002Fday, alcohol consumption more than 12 months)\n   7. history of severe pulmonary diseases (COPD, pulmonary encephalopathy)\n   8. history of serious cardiovascular disease (heart failure, severe hypertension)\n   9. infection and immune-related diseases affecting the central nervous system (systemic lupus erythematosus, undertreated HIV infection or a history of CNS syphilis infection, etc.)\n   10. metabolic and endocrine disorders (requiring new treatment or adjustment of current treatment for thyroid dysfunction, folate or vitamin B12 deficiency)\n   11. unstable psychosis or long-term use of antipsychotic drugs (more than 6 months)\n   12. history of malignant tumors (tumors of nervous system and other sites) active for nearly 1 year\n   13. contraindications for MRI (e.g. pacemakers, stents, claustrophobia, etc.) or do not cooperate or cannot carry out PET examination\n   14. uneducated illiterates\n   15. hearing impairment, visual impairment and poor coordination\n   16. withdraw or reject the study Subjective cognitive impairment (SCI) and Mild cognitive impairment (MCI)\n\n   \u003C!-- -->\n\n   1. With history of stroke and a neurological focal sign, the imaging findings are consistent with cerebral vascular disease (Fazekas score ≥ 2 points).\n   2. Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.).\n   3. Other systemic diseases that can cause cognitive impairment（such as liver, renal and thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.）.\n   4. Mental and neurodevelopmental retardation.\n   5. Other diseases known to cause cognitive impairment.\n   6. Contraindications to nuclear magnetics.\n   7. Suffering from a disease that cannot be combined with cognitive examination.\n   8. Refuse to draw blood.\n   9. Refuse to sign the informed consent at baseline Alzheimer's disease (AD)\n\n   \u003C!-- -->\n\n   1. Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.).\n   2. Other systemic diseases that can cause cognitive impairment（such as liver, renal and thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.）.\n   3. Mental and neurodevelopmental retardation.\n   4. Other diseases known to cause cognitive impairment.\n   5. Contraindications to nuclear magnetics.\n   6. Suffering from a disease that cannot be combined with cognitive examination.\n   7. Refuse to draw blood.\n   8. Refuse to sign the informed consent at baseline Vascular cognitive impairment (VCI)\n\n   \u003C!-- -->\n\n   1. Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.).\n   2. Other systemic diseases that can cause cognitive impairment（such as liver, renal, and thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.）.\n   3. Other diseases known to cause cognitive impairment.\n   4. Hereditary or inflammatory small vessel disease, such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).\n   5. Contraindications to nuclear magnetics.\n   6. Refuse to draw blood.\n   7. Refuse to sign the informed consent at baseline","99 Years",{"count":247,"type":20},4000,"This is a multi-center longitudinal study that consists of five cohorts: cognitive normal aging (CN), Subjective cognitive impairment (SCI), mild cognitive impairment (MCI), Alzheimer's disease (AD) and vascular cognitive impairment (VCI). The goals of this study are as follow: 1.To establish longitudinal cohort study database containing comprehensive epidemiological data, neuropsychological test data, laboratory parameters, image data and biological samples. 2. To determine the risk factors of AD and other dementias. 3. To explore the conversion rates from CN to SCI, MCI or AD and the risk factors as well as biomarkers for the progression from CN to SCI, MCI or AD. 4. To explore and validate blood, CSF, urine, imaging and other biomarkers for the early detection and progression of AD.",[250,75,251,27],"Aging","Alzheimer Disease","2022-07-18",{"date":254,"type":37},"2022-07-21",{"date":256,"type":37},"2021-01-10",{"date":258,"type":20},"2026-12",{"name":260,"class":44},"Second Affiliated Hospital, School of Medicine, Zhejiang University"]